South Korea approves Samsung Bioepis’ Herceptin biosimilar

November 10, 2017 10:51 AM

South Korea have approved Samfenet, a biosimilar drug referencing Roche’s Herceptin, marking the first oncology biosimilar to be sold by Samsung Bioepis in Korea, reported The Korea Herald yesterday.

The biosimilar drug, Samfenet, is approved in Korea for the treatment of metastatic breast cancer, early-stage breast cancer and metastatic gastric cancer. The company plans to begin selling the drug in Korea after selecting a marketing partner and completing drug pricing procedures.

Samsung Bioepis has recently gained the positive opinion from CHMP in Europe for Herceptin biosimilar and in Korea, the company has 3 biosimilars approved, each referencing Enbrel, Remicade and Humira, which are all anti-TNF drugs targeting autoimmune diseases.

Samsung is already selling its biosimilars referencing Enbrel and Remicade in Korea via its local marketing partner Yuhan Corp. It is slated to launch its Humira-referencing biosimilar after its Korean patent expires in January 2019.

Samsung also sells its Enbrel biosimilar in Europe and its Remicade biosimilar in Europe and the US. The company’s Humira biosimilar was approved in Europe this year as well.

 

Source: The Korea Herald

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!